US Patent Issued to TAIHO PHARMACEUTICAL on June 23 for "L718 and/or L792 mutant treatment-resistant EGFR inhibitor" (Japanese Inventors)

ALEXANDRIA, Va., July 15 -- United States Patent no. 12,661,356, issued on June 23, was assigned to TAIHO PHARMACEUTICAL Co. LTD. (Tokyo).

"L718 and/or L792 mutant treatment-resistant EGFR inhibitor" was invented by Shinichi Hasako (Tsukuba, Japan) and Takao Uno (Tsukuba, Japan).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides an antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of L718X mutation in exon 18 and L792X mutation in exon 20, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising(S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8.9-dihydropyrimido[5.4-b]indolizin-...